Browse > Article

ORI2 is a Strong Inhibitor of Coxsackievirus B4 Replication  

Lim, Byung-Kwan (Department of Biomedical Science, Jungwon University)
Jo, Soyeon (Department of Biomedical Science, Jungwon University)
Kim, Jin Hee (College of Herbal Bio-industry, Daegu Haany University)
Publication Information
Korean Journal of Pharmacognosy / v.45, no.4, 2014 , pp. 282-287 More about this Journal
Abstract
The ORI2 (3-[3,4-dihydroxyphenyl]acrylic acid 1-[3,4-dihydroxyphenyl]-2-methoxycarbonylethyl ester) was purified from the extract of Isodon excisus. We confirmed the antiviral effect of ORI2 in a coxsackievirus-induced pancreatitis model. Coxsackievirus B4 (CVB4) is a common cause of pancreatitis and may be reason of the type-1 diabetes. Anti-enteroviral compounds were screened by HeLa cell survival assay. Purified natural compounds were added to HeLa cells cultured 96-well plates after $10^4PFU/ml$ CVB4 pre-incubation for 30 min. ORI2 significantly improved HeLa cell survival in a dose-dependent manner. In addition, ORI2 (1 mM) treatment was dramatically decreased virus protease 2A induced eIF4G-I cleavage and viral VP1 capsid protein production. HeLa cell virus titers and viral RNA replication were significantly decreased in ORI2-treatment in a dose dependent manner (1 mM~0.001 mM). These results demonstrate that ORI2 has a strong antiviral effect. It was significantly decreased virus replication. ORI2 may be developed as a potential therapeutic agent for CVB4.
Keywords
Coxsackievirus B4; Pancreatitis; Isodon excisus; Diabetes;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yun, S. H., Lee, W. G., Kim, Y. C., Ju, E. S., Lim, B. K., Choi, J. O., Kim, D. K. and Jeon, E. S. (2012) Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J. Infect. Dis. 205: 491-497.   DOI   ScienceOn
2 Ramsingh, A. I., Lee, W. T., Collins, D. N. and Armstrong, L. E. (1997) Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein. J. Virol. 71: 8690-8697.
3 Ramsingh, A. I. (2008) CVB-induced pancreatitis and alterations in gene expression. Curr. Top Microbiol Immunol. 323: 241-258.
4 Ramsingh, A. I., Lee, W. T., Collins, D. N. and Armstrong, L. E. (1999) T cells contribute to disease severity during coxsackievirus B4 infection. J. Virol. 73: 3080-3086.
5 Caggana, M., Chan, P. and Ramsingh, A. (1993) Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype. J. Virol. 67: 4797-4803.
6 Stevens, T., Conwell, D. L. and Zuccaro, G. (2004) Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J. Gastroenterol. 99: 2256-2270.   DOI
7 Lee, C. H., Kim, J. H., Lee, H. J., Lee, S. M. and Kho, Y. H. (2001) Two new constituents of Isodon excisus and their evaluation in an apoptosis inhibition assay. J. Nat. Prod. 64: 659-660.   DOI   ScienceOn
8 Lim, B. K. and Kim, J. H. (2014) ORI2 inhibits coxsackievirus replication and myocardial inflammation in experimental murine myocarditis. Bio. Pharm. Bull. 37: 1650-1654.   DOI
9 Lim, B. K., Choi, J. H., Nam, J. H., Gil, C. O., Shin, J. O., Yun, S. H., Kim, D. K. and Jeon, E. S. (2006) Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc. Res. 71: 517-526.   DOI   ScienceOn
10 Lim, B. K., Choe, S. C., Shin, J. O., Ho, S. H., Kim, J. M., Yu, S. S., Kim, S. and Jeon, E. S. (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105: 1278-1281.
11 Huber, S. A. and Lodge, P. A. (1986) Coxsackievirus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am. J. Pathol. 122: 284-291.
12 Racaniello, V. R. Chapter24, The picornaviridae; The Viruses and Their Replication. Fields Virology (2007).
13 Tan, E. L., Wong, A. P. and Poh, C. L. (2010) Development of potential antiviral strategy against coxsackievirus B4. Virus Res. 150: 85-92.   DOI
14 Wang, S. M. and Liu, C. C. (2014) Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert. Rev. Anti. Infect. Ther. 12: 447-456.   DOI
15 Pinkert, S., Westermann, D., Wang, X., Klingel, K., Dorner A., Savvatis, K., Grossl, T., Krohn, S., Tschope, C., Zeichhardt, H., Kotsch, K., Weitmann, K., Hoffmann, W., Schultheiss, H. P., Spiller, O. B., Poller, W. and Fechner, H. (2009) Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus- adenovirus receptor. Circulation 120: 2358-2366.   DOI
16 Jaidane, H. and Hober, D. (2008) Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes. Diabetes Metab. 34: 537-548.   DOI
17 Potvin, D. M., Metzger, D. W., Lee, W. T., Collins, D. N. and Ramsingh, A. I. (2003) Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4. J. Virol. 77: 8272-8279.   DOI
18 De Palma, A. M., Thibaut, H. J., Li S., Van, Aelst I., Dillen, C., Swinnen, M., Verbeken, E., Neyts, J. and Opdenakker, G. (2009) Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis. J. Pathol. 217: 633-641.   DOI